Balloon Angioplasty vs. Cutting Balloon Angioplasty of Femoropopliteal Arteries- a Randomized Controlled Trial
|ClinicalTrials.gov Identifier: NCT00437905|
Recruitment Status : Terminated
First Posted : February 21, 2007
Last Update Posted : February 21, 2007
|Condition or disease||Intervention/treatment||Phase|
|Peripheral Vascular Disease Intermittent Claudication Atherosclerosis Angioplasty||Procedure: angioplasty||Phase 4|
Balloon Angioplasty is a minimal invasive technique for treatment of superficial femoropoliteal artery obstructions. Despite high initial success rate and an acceptably low complication rate, long-term-results are disappointing as restenosis may frequently occur. One of the hypothesis for the differences in the reported patency rates is that the amount of vessel trauma correlates directly to the prognosis (restenosis) of the treated vessel wall segment.
With the introduction of cutting balloons the problems of elastic recoil and residual stenosis might be resolved, by reduction of vessel wall trauma, vessel wall inflammation and consequently reduced neointima formation.
The promising results especially in coronary arteries led us to initiate a RCT comparing primary PTA vs. CB-PTA for treatment of femoropoliteal obstructions in patients with intermittent claudication or critical limb ischemia.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Balloon Angioplasty vs. Cutting Balloon Angioplasty of Femoropopliteal Arteries- a Randomized Controlled Trial|
|Study Start Date :||June 2003|
|Study Completion Date :||January 2007|
- course of postintervention inflammation as indicated by serum levels of C-reactive Protein (CRP+ us-CRP)
- occurence of restenosis within 6 months after endovascular treatment
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00437905
|Principal Investigator:||Jasmin Amighi, MD||Medical University of Vienna|
|Principal Investigator:||Martin Schillinger, MD||Medical University of Vienna|
|Principal Investigator:||Manfred Cejna, MD||Medical University of Vienna|